سعر ميجرتريبتان 10مجم 3 اقراص ذائبة 2026

Rizatriptan 10 mg orally disintegrating tablets, pack of 3 (Migtriptan, Organopharma).

• Acute treatment of migraine with or without aura.Population: Adults and pediatric patients 6 to 17 years oldDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions in adults (5% or more and greater than placebo): asthenia/fatigue, somnolence, pain/pressure sensation and dizziness; these appeared dose related.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Contraindicated in ischaemic coronary artery disease or coronary vasospasm (including Prinzmetal angina); history of stroke or TIA; peripheral vascular disease; ischaemic bowel disease; uncontrolled hypertension; use within 24 hours of another 5-HT1 agonist or an ergot-type drug; hemiplegic or basilar migraine; use with, or within 2 weeks of stopping, an MAO-A inhibitor; hypersensitivity to rizatriptan or excipients.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Serious cardiac events (myocardial ischaemia/infarction, Prinzmetal angina, life-threatening arrhythmias) have occurred; evaluate triptan-naive patients with cardiovascular risk factors before use. Chest, throat, neck or jaw pain/tightness/pressure is usually non-cardiac but needs evaluation if ischaemia is suspected. Cerebral haemorrhage, stroke and other vasospastic reactions have been reported.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Overuse of acute migraine drugs (10 or more days per month) can cause medication overuse headache; serotonin syndrome may occur, particularly with SSRIs, SNRIs, tricyclics or MAO inhibitors; significant blood pressure elevation, including hypertensive crisis, has been reported.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• PropranololPropranolol increases rizatriptan exposure (AUC about 70% higher); use the 5 mg dose with the limits stated in the label.DailyMed (U.S. National Library of Medicine)
• Ergot-containing drugs (e.g. dihydroergotamine, methysergide)Prolonged vasospastic reactions may be additive; do not use within 24 hours of each other.DailyMed (U.S. National Library of Medicine)
• Other 5-HT1 agonists (triptans)Additive vasospastic effects; do not use within 24 hours of each other.DailyMed (U.S. National Library of Medicine)

• Human data are not sufficient to determine a drug-associated risk of major birth defects or miscarriage; the Maxalt pregnancy registry (1998-2018) identified no pattern of congenital anomalies, but numbers were small. Developmental toxicity occurred in animals at exposures above therapeutic levels.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk or effects on the breastfed infant; in rats, milk levels were about 6 times maternal plasma levels. Weigh the benefits of breastfeeding against the mother's need and possible infant effects.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Rizatriptan: Binds with high affinity to 5-HT1B and 5-HT1D receptors; thought to relieve migraine by agonist effects on these receptors on intracranial blood vessels and sensory trigeminal nerves.